ALLK Allakos Inc.

37.68
+2.52  (+7%)
Previous Close 35.16
Open 35.54
Price To Book 8.1
Market Cap 1586820063
Shares 42,113,059
Volume 304,663
Short Ratio
Av. Daily Volume 365,219

NewsSee all news

  1. Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
  2. Allakos Enters Oversold Territory
  3. Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
  4. Allakos to Host Investor Day on February 19 in New York City
  5. Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

SEC filingsSee all SEC filings

  1. 8-K - Current report 19614332
  2. 8-K - Current report 19613467
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19599266
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19594510
  5. 8-K - Current report 19581942

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due late 1Q/Early 2Q 2019.
AK002
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
AK002
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002
Chronic Urticaria
Phase 2 top-line data due mid-2019.
AK002
Eosinophilic Gastritis

Latest News

  1. Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
  2. Allakos Enters Oversold Territory
  3. Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
  4. Allakos to Host Investor Day on February 19 in New York City
  5. Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
  6. Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
  7. Here are the winners and losers from Bay Area's IPO class of 2018
  8. 5 Best-Performing IPOs of 2018
  9. Assessing the Performance of 2018’s Major IPOs
  10. Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
  11. Here's how much better insiders have profited from this year's IPO boom
  12. Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?
  13. Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

SEC Filings

  1. 8-K - Current report 19614332
  2. 8-K - Current report 19613467
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19599266
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 19594510
  5. 8-K - Current report 19581942
  6. 8-K - Current report 19561655
  7. 8-K - Current report 19547153
  8. 8-K - Current report 19512230
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170244
  10. 8-K - Current report 181169675